Venture Capitals from Verve Ventures, MMC Ventures, HTGF, and Sofinnova Partners share their cancer startup picks to keep an eye on going into the second half of 2023. Perman Jorayev, VC investor, of Verve Ventures mentions Omniscope as one to watch:
"Barcelona-based Omniscope AI has developed a platform to perform high-precision immune profiling — the process of understanding why people respond differently to viruses — enabled by its AI platform and disease-specific data libraries. Moving forward, the company will be rolling out different products in immunotherapy (OS-IMT) and patient monitoring (OS-MRD) across different types of cancer."
More in the article at Sifted.